Evidence map›Paper›PMID 20878371›Full record

ReviewCurrent rheumatology reports2010

ANCA-associated small vessel vasculitis: clinical and therapeutic advances.

Niveditha Mohan, Gail S Kerr

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Niveditha MohanUniversity of Pittsburgh, Arthritis and Autoimmunity Center, Pittsburgh, PA 15213, USA. nmohan@pol.net
Gail S Kerr

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antineutrophil cytoplasmic antibodies-associated small vessel vasculitides are an encompassing group of diseases defined by serologic and anatomic criteria. Their diverse phenotype is an ongoing diagnostic challenge, and early diagnosis is paramount in optimizing outcomes and minimizing morbidity. Therapies targeted at components of the immune system, both cellular and cytokine, have been assessed as both inducers and sustainers of remission. As current data provide clarity in pathogenesis, treatment options and strategies have been evaluated to improve outcomes. However, challenges remain in limiting disease flares and therapy-associated morbidities, and cures are achieved only in cases in which a clear culprit exists.

Indexed as

AnimalsAntibodies, Antineutrophil CytoplasmicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisDisease Models, AnimalHumansImmunologic FactorsPractice Guidelines as TopicRandomized Controlled Trials as TopicAntibodies, Antineutrophil CytoplasmicImmunologic Factors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.